Market Spotlight: Hodgkin’s Lymphoma
Market Spotlight: Hodgkin’s Lymphoma
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2017, there were 78,600 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,000 incident cases by 2026.
- In the same year, there were approximately 272,100 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 297,700 five-year prevalent cases by 2026.
- The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.
- The majority of the industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II, with no drugs in Phase III.
- Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the oral or intravenous routes, with only one product being tested in an intratumoral formulation.
- High-impact upcoming events for drugs in the Hodgkin’s lymphoma space comprise topline Phase IIa trial results for AFM13, topline Phase II trial results for ADCT-301, and topline Phase III trial results and an estimated PDUFA date for Keytruda.
- The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 59.4%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 43 licensing and asset acquisition deals involving Hodgkin’s lymphoma drugs during 2014–19. The largest deal was the $1,456m collaboration agreement in 2015 between Eli Lilly and Innovent Biologics for the development and potential commercialization of at least three cancer treatments over the next decade.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
- The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
- Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 49 trials.
- Takeda leads industry sponsors with the highest number of clinical trials for Hodgkin’s lymphoma, followed by Bristol-Myers Squibb.
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
10 Radiation therapy
11 Stem cell transplantation (SCT)
17 MARKETED DRUGS
20 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Folotyn for Hodgkin’s Lymphoma (January 17, 2019)
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 A Slew Of Standard Reviews
31 China’s Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval
32 PROBABILITY OF SUCCESS
33 LICENSING AND ASSET ACQUISITION DEALS
33 BeiGene Reacquires Tislelizumab Ahead Of Bristol/Celgene Merger
34 PARENT PATENTS
35 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
40 Prescription information
LIST OF FIGURES
14 Figure 1: Trends in incident cases of Hodgkin’s lymphoma, 2017–26
20 Figure 2: Overview of pipeline drugs for Hodgkin’s lymphoma in the US
21 Figure 3: Pipeline drugs for Hodgkin’s lymphoma, by company
21 Figure 4: Pipeline drugs for Hodgkin’s lymphoma, by drug type
21 Figure 5: Pipeline drugs for Hodgkin’s lymphoma, by classification
30 Figure 6: Key upcoming events in Hodgkin’s lymphoma
32 Figure 7: Probability of success in the Hodgkin’s lymphoma pipeline
33 Figure 8: Licensing and asset acquisition deals in Hodgkin’s lymphoma, 2014–19
34 Figure 9: Parent patents in Hodgkin’s lymphoma
36 Figure 10: Clinical trials in Hodgkin’s lymphoma
36 Figure 11: Top 10 drugs for clinical trials in Hodgkin’s lymphoma
37 Figure 12: Top 10 companies for clinical trials in Hodgkin’s lymphoma
37 Figure 13: Trial locations in Hodgkin’s lymphoma
38 Figure 14: Hodgkin’s lymphoma trials status
39 Figure 15: Hodgkin’s lymphoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of Hodgkin’s lymphoma, 2017–26
15 Table 2: Five-year prevalent cases of Hodgkin’s lymphoma, 2017–26
18 Table 3: Marketed drugs for Hodgkin’s lymphoma
23 Table 4: Pipeline drugs for Hodgkin’s lymphoma in the US
28 Table 5: Folotyn for Hodgkin’s Lymphoma (January 17, 2019)
35 Table 6: Historical global sales, by drug ($m), 2014–18
35 Table 7: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.